JP2014221834A5 - - Google Patents

Download PDF

Info

Publication number
JP2014221834A5
JP2014221834A5 JP2014167336A JP2014167336A JP2014221834A5 JP 2014221834 A5 JP2014221834 A5 JP 2014221834A5 JP 2014167336 A JP2014167336 A JP 2014167336A JP 2014167336 A JP2014167336 A JP 2014167336A JP 2014221834 A5 JP2014221834 A5 JP 2014221834A5
Authority
JP
Japan
Prior art keywords
mir
tumor
level
subject
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014167336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014221834A (ja
JP6110346B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014221834A publication Critical patent/JP2014221834A/ja
Publication of JP2014221834A5 publication Critical patent/JP2014221834A5/ja
Application granted granted Critical
Publication of JP6110346B2 publication Critical patent/JP6110346B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014167336A 2008-12-05 2014-08-20 miR−31に関連する組成物および方法 Expired - Fee Related JP6110346B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12032208P 2008-12-05 2008-12-05
US61/120,322 2008-12-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011539777A Division JP2012511031A (ja) 2008-12-05 2009-12-07 miR−31に関連する組成物および方法

Publications (3)

Publication Number Publication Date
JP2014221834A JP2014221834A (ja) 2014-11-27
JP2014221834A5 true JP2014221834A5 (https=) 2015-02-19
JP6110346B2 JP6110346B2 (ja) 2017-04-05

Family

ID=42233912

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011539777A Pending JP2012511031A (ja) 2008-12-05 2009-12-07 miR−31に関連する組成物および方法
JP2014167336A Expired - Fee Related JP6110346B2 (ja) 2008-12-05 2014-08-20 miR−31に関連する組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011539777A Pending JP2012511031A (ja) 2008-12-05 2009-12-07 miR−31に関連する組成物および方法

Country Status (6)

Country Link
US (2) US20120041048A1 (https=)
EP (1) EP2370091B1 (https=)
JP (2) JP2012511031A (https=)
AU (1) AU2009322137B2 (https=)
CA (1) CA2745919A1 (https=)
WO (1) WO2010065961A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723349A4 (en) * 2011-06-27 2015-01-14 Medimmune Llc MICROARN-31 COMPOSITIONS AND METHODS OF USE IN AUTOIMMUNE DISEASES
CN102776191A (zh) * 2012-07-20 2012-11-14 苏州大学 一种微小rna用于调控cd86的基因表达
EP3591050B1 (en) * 2013-09-06 2024-01-31 The University of Tokyo Use of rhoa in cancer diagnosis and inhibitor screening
WO2015164786A1 (en) * 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
EP2940151A1 (en) * 2014-05-02 2015-11-04 Ruprecht-Karls-Universität Heidelberg Circulating miRNAs as early detection marker and prognostic marker
US9623040B2 (en) * 2014-07-14 2017-04-18 The Board Of Trustees Of The Leland Stanford Junior University Immunomodulation by controlling expression levels of microRNAs in dendritic cells
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
WO2018183594A1 (en) * 2017-03-29 2018-10-04 Children's Hospital Medical Center Nucleic acid molecules and their methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1726199A (en) * 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
ATE386804T1 (de) * 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
JP2006519008A (ja) * 2003-02-10 2006-08-24 独立行政法人産業技術総合研究所 哺乳動物細胞の調節
US20080014579A1 (en) * 2003-02-11 2008-01-17 Affymetrix, Inc. Gene expression profiling in colon cancers
US20050193432A1 (en) 2003-11-18 2005-09-01 Whitehead Institute For Biomedical Research Xenograft model of functional normal and malignant human breast tissues in rodents and methods thereof
WO2005113770A1 (en) * 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
EP2302055B1 (en) * 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006061430A2 (en) * 2004-12-10 2006-06-15 Proskelia Bone metastasis markers as a target regulating bone metastasis and bone development
US7666595B2 (en) * 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1969147B1 (en) * 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
US20080199961A1 (en) 2006-08-25 2008-08-21 Avi Biopharma, Inc. ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
WO2008036776A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2009070767A2 (en) 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
US20110009469A1 (en) * 2007-12-05 2011-01-13 The Johns Hopkins University Compositions and methods of treating neoplasia
WO2011047147A1 (en) * 2009-10-14 2011-04-21 Baylor College Of Medicine Microrna mirna-31 as a therapeutic approach for the treatment of cancer
WO2012024612A1 (en) * 2010-08-20 2012-02-23 Pangea Biosciences, Inc. Cancer diagnostic and cancer therapeutic

Similar Documents

Publication Publication Date Title
JP2014221834A5 (https=)
Kandimalla et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers
KR102565758B1 (ko) 암 예후 예측방법 및 이의 조성물
Guo et al. Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer
Fedotovskayad Genes and athletic performance: an update
Ho et al. Deregulation of Rab and Rab effector genes in bladder cancer
Lorenzen et al. Long noncoding RNAs in kidney and cardiovascular diseases
Terekhanova et al. Fast evolution from precast bricks: genomics of young freshwater populations of threespine stickleback Gasterosteus aculeatus
US10041126B2 (en) Monocyte biomarkers for cancer detection
CN113228190B (zh) 分类和/或鉴定癌症亚型的系统和方法
Yang et al. LncRNA SNHG12 regulated the proliferation of gastric carcinoma cell BGC-823 by targeting microRNA-199a/b-5p.
JP2014532428A5 (https=)
Liu et al. Single nucleotide polymorphisms of microRNA processing machinery genes and outcome of hepatocellular carcinoma
CA2859663A1 (en) Identification of multigene biomarkers
Wright et al. Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM)
Wang et al. A common genetic variation in the promoter of miR-107 is associated with gastric adenocarcinoma susceptibility and survival
TW201309805A (zh) 預測大腸直腸癌復發的生物標記
Franceschi et al. Investigating molecular alterations to profile short-and long-term recurrence-free survival in patients with primary glioblastoma
WO2017147593A2 (en) Long intergenic non-coding rna as pan-cancer biomarker
Wu et al. Association on polymorphisms in LncRNA HOTAIR and susceptibility to HNSCC in Chinese population
CA3141356A1 (en) Pan-cancer transcriptional signature
US20170058354A1 (en) Method and composition for diagnosis of aggressive prostate cancer
KR20110015013A (ko) 결장직장암의 평가 방법 및 여기에 사용하기 위한 조성물
Peng et al. Comprehensive landscape of m6A regulator-related gene patterns and tumor microenvironment infiltration characterization in gastric cancer
Alonso‐Dominguez et al. PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase